立体定向放射外科治疗无症状颅底脑膜瘤的结局
该回顾性研究纳入1997至2019年接受单次伽玛刀放射外科(GKRS)治疗的无症状颅底脑膜瘤患者,评估其安全性与疗效。中位临床随访58.5个月,无手术或肿瘤相关死亡,永久性神经并发症发生率为2.75%,平均肿瘤体积自4.04 cc显著缩小至2.73 cc(p<0.001)。作者认为相较自然病史研究,GKRS可使绝大多数患者获得长期肿瘤控制与神经功能保全。
要点
- 单次GKRS治疗无症状颅底脑膜瘤未观察到手术或肿瘤相关死亡。
- 永久性神经并发症发生率为2.75%,平均肿瘤体积显著缩小。
- 较高的边缘剂量与末次随访时肿瘤退缩相关(HR=1.351;95%CI [1.094-1.669];p=0.05)。
核心结论
- 相较自然病史研究,GKRS可使绝大多数无症状颅底脑膜瘤患者获得长期肿瘤控制与神经功能保全。
- 无症状颅底脑膜瘤的最佳管理方式仍需进一步研究确定。
研究设计与样本
- 回顾性研究,纳入1997至2019年接受GKRS治疗的无症状颅底脑膜瘤患者。
- 分析患者临床影像资料、肿瘤特征及操作细节。
主要发现
- 中位临床随访58.5个月(范围14-150个月),未观察到与操作或治疗肿瘤相关的死亡。
- 永久性神经并发症发生率为2.75%。
- 平均肿瘤体积自放射外科前的4.04 cc(SD 3.09 cc)降至末次随访的2.73 cc(SD 2.24 cc),差异有统计学意义(p<0.001)。
- 较高的边缘剂量与末次随访时肿瘤退缩相关(HR=1.351;95%CI [1.094-1.669];p=0.05)。
关键数值与推荐
- 结局良好定义为无操作相关死亡或永久性神经并发症,且影像学证实肿瘤控制。
- 肿瘤进展定义为体积较基线增加>20%,退缩定义为较基线减少>20%,体积在基线±20%以内视为稳定。
临床怎么用
- 对无症状颅底脑膜瘤患者,GKRS可作为获得长期肿瘤控制与神经功能保全的治疗选择。
- 随访中需结合影像学体积变化(>20%为进展或退缩)评估疗效。
局限性
- 无症状颅底脑膜瘤的最佳管理策略尚需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Optimal management of asymptomatic skull base meningiomas is controversial. We evaluated the safety and efficiency of Gamma Knife radiosurgery (GKRS) for the management of asymptomatic skull base meningiomas. METHODS: This retrospective study involved patients managed with GKRS for asymptomatic, skull base meningiomas from 1997 to 2019. Patient clinico-radiologic data, tumor characteristics, and procedural details were analyzed. Favorable outcome was defined as lack of procedure-related mortality or permanent neurologic morbidity and radiologic evidence of tumor control. Tumor progression and regression were defined as an increase or decrease of > 20% in volume from baseline to the last neuroimaging study respectively. Tumor volumes within ± 20% of baseline volume were considered stable. RESULTS: Thirty-seven patients (30 women), median age 68 years old (range 42-83 months) were managed with a single-session GKRS for 40 asymptomatic, skull base meningiomas. At a median clinical follow-up of 58.5 months (range 14-150 months), no mortality associated with the procedure or the treated tumor was noted. Permanent neurologic morbidity was 2.75%. There was a statistically significant decrease in mean tumor volume (p < 0.001) from 4.04 cc (SD 3.09 cc) prior to radiosurgery to 2.73 cc (SD 2.24 cc) at last follow-up. Higher margin dose was associated with tumor regression at last follow-up (HR = 1.351; 95%CI [1.094-1.669]; p = 0.05). CONCLUSION: As compared to natural history studies, GKRS affords long-standing tumor control and neurologic preservation in the vast majority of patients treated for asymptomatic, skull base meningiomas. Further study is necessary to identify the optimal management of asymptomatic skull base meningiomas.
引用
- Pikis S, Bunevicius A, Sheehan J, et al. Outcomes from treatment of asymptomatic skull base meningioma with stereotactic radiosurgery. Acta Neurochir (Wien). 2020. PMID: 33211178. doi:10.1007/s00701-020-04648-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。